1 active not recruiting, 1 completed, 1 recruiting. 3 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
Follow Thinness: new trials by email Literature Review of Thinness trials Research Report on Thinness
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors SXRN, Placebo - Advanced Cancer, Cachexia | Early Phase 1 | Recruiting | Jiangsu Nutai Biologics Co., Ltd | 28 | 2024-09-02 | 2026-05-15 |
| Ruxolitinib for Cancer Cachexia Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients. - Stage IV Non-small Cell Lung Cancer, Cachexia | Early Phase 1 | Active not recruiting | Tu Dan | 10 | 2022-02-23 | 2026-07-07 |
| Study on the Effect of Fish Oil and Appetite Fish oil - Obesity, Cachexia | Early Phase 1 | Completed | AAstrup | 20 | 2011-10-01 | 2012-11-12 |
Cachexia (3) · Anorexia (1) · Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1) · Muscular Atrophy (1) · Obesity (1)
Body Weight (3) · Body Weight Changes (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Weight Loss (3) · Atrophy (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Lung Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Nervous System Diseases (1) · Neurologic Manifestations (1) · Neuromuscular Manifestations (1)
Fish Oils (1)
AAstrup (1) · Jiangsu Nutai Biologics Co., Ltd (1) · Tu Dan (1)
China (1) · Denmark (1) · United States (1)
Lotte Lauritzen, PhD (1) · Tu Dan, MD (1)